Slide 1: Corporate Presentation
Corporate Presentation March 30! 2023
Slide 2: No Offer or Solicitation
No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation ofan offer to sell or the solicitation ofan offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prio
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding management's intentions, plans, beliefs, expectations or forecasts for the future, including, but not
Slide 4: EIP Pharma at a Glance
EIP Pharma at a Glance E | Pp Late Clinical Stage CNS Company PHARMA Differentiated approach to age-related neurologic disorders with a late-stage lead clinical asset; pipeline of additional indications and second asset Phase 2b Ready Lead Drug Candidate Neflamapimod has the potential to be the firs
Slide 5: Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration
Opportunity for Therapeutics Targeting Basal E | Pp Forebrain Cholinergic Degeneration SERIE: + Age-related degeneration of the basal forebrain cholinergic system plays major role in many neurologic disorders: er Basal Forebrain — Dementia with Lewy bodies (DLB), where it is the primary pathology ~
Slide 6: EIP Pharma Pipeline
EIP Pharma Pipeline @EIP EIB Corn: PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Rights NEFLAMAPIMOD. Dementia with Lewy bodies* Circulation Ischemic Stroke Disease (EOAD) Mw EIP200 (novel co-crystal) Mutt ens ww *Received FDA Fast Track designation ww ENTERING PHASE 2B
Slide 7: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) What is DLB? + Disease associated with abnormal deposits of a protein called alpha-synuciein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain ‘whose changes, in tum, can lead to problems with thinking, movement, behavior, and mood Affect
Slide 8: Neflamapimod for DLB: Well-Positioned Commercially
Neflamapimod for DLB: Well-Positioned E | Pp Commercially PHARMA Approximately 700,000 in each of — fu Increasing awareness >$5B US Peak D 2 of disease Sales for the First to Market Diagnosed and managed by neurologists Specialist Dis Relative to AD: + Greater rate of cognition decline + Lower quali
Slide 9: Neflamapimod: Background
Neflamapimod: Background E | P PHARMA + Potent, highly selective, blood-brain-barrier penetrant oral small molecule inhibitor of p38a. p38a/RabS Axis is a Convergence Point Underlying + Licensed in 2014 from Vertex Pharmaceuticals, which a rane pala had: pcre “PF 1.46 (neuroinflammation) Discovered
Slide 10: Robust Preclinical Pharmacology Package
Robust Preclinical Pharmacology Package E | Pp PHARMA In Ts2 mice 4 weeks neflamapimod ; In Vitro \v) treatment reverses neurodegenerative process in the basal forebrain and Demonstrated potent effects, with ICs restores functional deficits (Nat. between 20nM and 30nM Communications, 2022) Peaesenas
Slide 11: Neflamapimod Reverses Cholinergic Dysfunction and Degeneration
Neflamapimod Reverses Cholinergic Dysfunction and Degeneration Ts2 mice Down Syndrome transgenic mouse model Develop adult-onset basal forebrain cholinergic degeneration Treated with vehicle or 3 mg/kg NFMD BID x 28 days Reversed basal forebrain cholinergic neuron loss and restored cholinergic funct
Slide 12: Neflamapimod Appears to Reverse Basal Forebrain Atrophy, assessed by MRI
Neflamapimod Appears to Reverse Basal Forebrain Atrophy, assessed by MRI Neflamapimod treatment is associated wit 15 Early AD patients treated with neflamapimod Bis , zw : WAS i «te y + 5 le Baseline 12.wecks Follow-up Be treatment i ve § g increased basal forebrain volume and functional connecti 20
Slide 13: Neflamapimod: Toxicology, Clinical Safety, Clinical Efficacy, Development Status
Neflamapimod: Toxicology Clinical Safety Clinical Efficacy Development Status E | Pp PHARMA Completed long-term toxicology studies in two species At 40 mg thrice daily in humans greater than 10-fold safety margin to no-adverse- event level in long-term animal toxicity studies Simple 3-step drug synt
Slide 14: Target Engagement: Neflamapimod Reduces CSF tau levels in Early AD
Target Engagement: Neflamapimod Reduces Cerebrospinal fluid (CSF) tau levels in patients with Early AD In preclinical studies, inhibition of p38c. reduces tau phosphorylation and aggrogation linical Trial Results with Neflamapimod EIP PHARMA Selective suppression of the a isoform of | O-~ p38 MAPK r
Slide 15: Phase 2a Exploratory Clinical Study in Dementia with Lewy Bodies
Phase 2a Exploratory Clinical Study in E | Pp Dementia with Lewy Bodies (DLB) PHARMA Outcome Measures i + DLB-specific / / Neuropsychological Test : Battery (NTB, a cognitive test Patients + Mild-to-Moderate DLB by consensus criteria (Mckeith, Neurology, 2017) ail " 5 . + Dementia Severity, assesse:
Slide 16: AscenD-LB Outcome Measures
AscenD-LB Outcome Measures Clinical Dementia Rating Sum of Boxes (CDR-SB, Total Score = 0-18) Cognitive Domains: + Memory (0-3) + Orientation (0-3) + Judgement and Reasoning (0-3) Functional Domains + Community Affairs (0-3) + Home & Hobbies (0-3) + Personal Care (0-3) Neuropsychological Test Batter
Slide 17: AscenD-LB Efficacy Results
AscenD-LB Efficacy Results Comparison of all neflamapimod {40mg BID and 4omg TID) with placebo Comparison of neflamapimod 4omg TID with placebo Drug-Placebo Drug-Plecebo Difference On- Difference On- Study Outcome Measure | Study(95%Cl) p-value (e5%C1) p-value ee 0.56 corse 0.023 (0.830.068) (0.96,-
Slide 18: Biomarker Results Support Enrichment Strategy for Future Trials
Biomarker Results Support Enrichment Y cenD-LB Strategy for Future Trials * 35-50% of patients with DLB have Fi ‘ ‘ biomarker evidence of Alzheimer's Effect Size at 40mg TID in patients disease (AD) with plasma ptau181 below cut-off — Represent patients with extensive neurodegeneration (neuronal los
Slide 19: Learnings from Phase 2a Study That Enhance Probability of Success in Phase 2b
Learnings from Phase 2a Study That Enhance E | Pp Probability of Success in Phase 2b SERIE: * Optimal dose is 40mg TID * Clinical endpoints that can detect effects on both cognitive and motor function (specifically, CDR-SB and TUG) perform better than endpoints that are purely focused on evaluating
Slide 20: Phase 2b Confirmatory Study in DLB
Phase 2b Confirmatory Study in DLB E | P PHARMA Protocol EIP21-NFD-504 Outcome Measures _/ + 48: CDR-Sum of Boxes + 2: Cognition assessed by DLB-specific Neuropsychotogical Test Battery (NTB), CGIC; Motor Function, assessed by Timed Up and Go (TUG) test nts DLB by consensus criteria (McKeith, Neurol
Slide 21: Potential to Broaden Opportunity
Potential to Broaden Opportunity E | Pp PHARMA » Additional indications in which dysfunction or degeneration of basal forebrain cholinergic system plays major pathogenic role: — Functional recovery after anterior circulation ischemic stroke — Alzheimer’s disease (AD): Early-onset AD (EOAD) or Late O
Slide 22: Leadership Team
Leadership Team John Alam, MD President, CEO & Co-Founder 4, vittex Biogen EIP PHARMA Kelly Blackburn VP, Clinical Development @ esr vuthex AA MILLENNIUM syivie Gregoire, PharmD Executive Chair & Co-Founder > merc *Biogen Shire $9, Darryl Patrick, DVM, PhO VP, Non-Clinical Development © merc William
Slide 23: Key Upcoming Anticipated Milestones/Catalysts
Key Upcoming Anticipated E | P Milestones/Catalysts PHARMA v NIA approves $21M grant for Q Close merger transaction; Q Complete enrollment in Phase Phase 2b begin trading as a public 2b DLB study (1H) company (mid-year) ¥ Signed merger agreement Q_ Report data from placebo- with Diffusion Pharma Q_
Slide 24: Summary
Summary E | Pp PHARMA @ Differentiated Approach to Age-related Neurologic Disorders with a Late-Stage Asset Major value creation potential in phase 2b read-out in dementia with Lewy bodies EIP. Experienced Management Team and Board of Directors Pharma Potential to broaden opportunity through additio
Slide 25: Thank you
| eh wes @EIP ~ - SS PHARMA N Thank you q \